Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Cardiac Surgical Procedures Clinical Trial

Official title:

Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06012968
• Other study ID #: mzk202301
• Status: Recruiting
• Start date: August 2023
• Est. completion date: October 2023

Study information

• Verified date: August 2023
• Source: Wuhan Union Hospital, China
• Contact: Qingping Wu, doctor
• Phone: 13971605283
• Email: wqp1968[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study intends to include hypertrophic cardiomyopathy patients over 18 years old who underwent cardiac surgery in our hospital. Patients were divided into medication group and control group according to the use of gastrodin during operation. The patients ' myocardial tissue samples were collected, the postoperative prognosis data were observed and recorded, and the data were analyzed. The degree of myocardial tissue cell damage and postoperative clinical outcomes were compared between the two groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: October 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with hypertrophic cardiomyopathy aged=18 years, regardless of gender;
• Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery;
• Signed informed consent, good compliance.

Exclusion Criteria:

• suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.);
• moderate to severe malnutrition, moderate to severe anemia;
• persistent infection;
• severe preoperative underlying diseases (such as severe liver and kidney dysfunction)

Related Conditions & MeSH terms

• Cardiac Surgical Procedures

Locations

Country	Name	City	State
China	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan Union Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Degree of myocardial cell injury	Postoperative myocardial injury marker serum concentration, postoperative cardiac function ultrasound index	During postoperative hospitalization stay, an average of about two weeks